Talphera, Inc.
TLPHHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 23, 2026
Scan Results
Daily timeframeTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. With a market capitalization of $67.0M, it sits in micro-cap territory. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Market Cap
$67.0M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-4.78
EPS (TTM)
$-0.28
EPS (Fwd)
$-0.27
ROE
-118.4%
ROA
-40.2%
Cash
$21.1M
Total Debt
$6.5M
Free CF
-$5.8M
52W Change
193.2%
Annual Financials
Cash vs Debt
Where TLPH stands vs its 150-day and 200-day moving averages
As of the July 16, 2026 close, TLPH finished 53.19% above its 150-day moving average ($0.94) and 44.00% above its 200-day moving average ($1.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLPH overbought or oversold?
At the July 16, 2026 close, TLPH's RSI(14) was 81.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $21.1M in cash comfortably exceeding the $6.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$5.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -118.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, TLPH has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TLPH.